科华生物(002022.SZ)发布上半年业绩，归母净亏损1.33亿元

Core Viewpoint - Kehua Bio's 2025 semi-annual report indicates a significant decline in revenue and a net loss for the company [1] Financial Performance - The company achieved an operating revenue of 794 million yuan, representing a year-on-year decrease of 12.65% [1] - The net loss attributable to shareholders of the listed company was 133 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 140 million yuan [1] - The basic loss per share was 0.2595 yuan [1]